Kornimate/medical-research-clean huggingface dataset:
the effect of fact versus myth messages on receipt of influenza vaccination

Conditions: Influenza Vaccination

Summary: the purpose of this study is to evaluate whether message design of educational materials increases vaccination rates among participants.


Eligibility criteria:
inclusion criteria: * participant must have a scheduled appointment at least 6 weeks in advance in either the gim or geriatrics clinics at nmff. * participant must be a patient of northwestern medical faculty foundation. * participant does not intend to receive the influenza vaccine. exclusion criteria: * participant has a diagnosis of alzheimer's disease or dementia * participant has received an influenza vaccination during either the last influenza season or the current. * the scheduled visit is the participant's first time being seen by this doctor (appointment is to establish care in the clinic).

Keywords: education vaccination preventive service prevention & control
travoprost 0.004% versus pilocarpine 1% in patients with chronic angle closure glaucoma (cacg)

Conditions: Angle-closure Glaucoma

Summary: the purpose of this study is to demonstrate that the intraocular pressure (iop) lowering efficacy of travoprost ophthalmic solution 0.004% is superior to that of pilocarpine 1% in patients with chronic angle-closure glaucoma (cacg).


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * chronic angle closure glaucoma (cacg) * 21-35 millimeters mercury mean intraocular pressure on eligibility visit day at 9 am * peripheral iridotomy performed ≥ 1 month prior to the screening visit * anterior chamber angle in which the trabecular meshwork is not visible for ≥180 degrees in gonioscopy without indentation * peripheral anterior synechiae (pas) exclusion criteria: * traumatic damage of the anterior chamber angle * history of ocular inflammation or surgery (except for iridotomy) ≤ 3 months * patients who cannot be safely discontinued from use of all ocular hypotensive medication(s) for 12 days to 14 weeks * visual acuity ≥ 1.0 * contact lenses wearer

Keywords: iop lowering efficacy cacg
new three-dimensional methods of analysis for the detection of coronary artery disease by dobutamine stress echocardiography

Conditions: Coronary Artery Disease; Echocardiography, Stress

Summary: the investigators are going to recruit patients who have a scheduled elective coronary angiography and going to do a dobutamin stress echography (dse) before the coronary examination. next to a regular 2d-dse, the investigators will perform an 3-dimensional dse, incl ventriculography. in the interventional part (coronary angiography), they will measure each stenosis with fractional flow-reserve (ffr)and herewith graduate its stenosis severity.

background coronary heart disease is the leading cause of death worldwide. non-invasive, radiation-free diagnostic needs further improvement. in this study, the investigators test the hypothesis that their method, which measures the myocardial deformation using 3d echocardiography is superior to previous ultrasound technologies with regard to diagnosis of stable coronary artery disease. the aim is establish an improved, non-invasive method to diagnose stable coronary artery disease. objective the investigators want to investigate if a 3d-speckle-tracking is superior and more accurate in predicting hemodynamically significant coronary artery stenosis than predicted by 2d echocardiography? the reference variable for the hemodynamic significance of coronary artery stenosis is invasively measured by coronary flow reserve (cfr) in consideration of collateral flow (cfi). methods this is a prospective observational study. the investigators will include 100 persons who are scheduled for an elective coronary angiography. a regular 2d-stress echocardiography according to the international guidelines will be performed (incl. plax, sax, 2cv, 4cv). the classification of regional wall motion abnormality is carried out according to the internationally recognized standards in 16 myocardial segments of the lv, with a grading of wall thickening (0 = dyskinetic, akinetic = 1, 2 = hypokinetic, 3 = normal). in addition, a 3d speckle tracking is performed after data transfer. to determine the functional relevance of any stenosis (reference method) a flow reserve in a maximum of two coronary arteries will be performed. test accuracy of 2d stress echocardiography and the new 3d method for detecting a significant stenosis (cfi \<2) are then compared.

Eligibility criteria:
inclusion criteria: * scheduled elective coronary angiography * age \>/= 18 years * written informed consent exclusion criteria * age \< 18 years * acute coronary syndrome * unstable angina pectoris * coronary 3-vessel disease * left-main artery affected * situation after myocardial infarction * coronary anomaly * situation after coronary bypass * congenital heart disease * pacemaker * any contraindication concerning stress-echo

Keywords: echocardiography, stress echocardiography, three-dimensional coronary artery disease fractional flow reserve, myocardial coronary circulation
t-wave alternans (twa) reproducibility in cad patients

Conditions: Coronary Artery Disease

Summary: microvolt t-wave alternans (mtwa) is a relatively new non-invasive method for identifying patients at increased risk of sudden death from ventricular arrhythmias. mtwa can be measured during a routine exercise test, during pharmacologic stress or during cardiac pacing. its clinical performance compares favorably with that of other non-invasive risk stratifiers and invasive electophysiologic studies. the purpose of the present study is to define the reproducibility of mtwa testing.

the study will be performed in the cardiac rehabilitation center at assaf harofeh medical center. patients with coronary artery disease will be eligible to enroll. patient will undergo an exercise test on a stationary bicycle. twa will be measured at heart rate of 105 and 115 bpm. the test will be repeated one week later in the same fashion. the patient will continue follow-up in the rehabilitation center as dictated by the rehabilitation program. patients will be kept on their regular medications and there will be no change of the medications from the first twa measurement to the second.

Eligibility criteria:
inclusion criteria: 1. patients enrolled in the cardiac rehabilitation center program 2. patients with cad 3. age \>18 and \< 80 yo 4. patients with a pacemaker or defibrillator with normal av conduction exclusion criteria: 1. patients with chronic af 2. patients with multiple apb's or pvc's 3. patients who are unable to increase their heart rate to 115 bpm and don't have a pacemaker. 4. patients who are unable to exercise on a bicycle.

Keywords: microvolt t wave alternans reproducibility
role of home-based transcutaneous electrical acustimulation for treatment of pain in patients with chronic pancreatitis

Conditions: Chronic Pancreatitis

Summary: this research is studying a new noninvasive device-based therapy called transcutaneous electrical acustimulation (tea) to learn about its safety and how well it works as a treatment of pain in chronic pancreatitis. the purpose of this study is to investigate the potential of tea to treat abdominal pain in patients with chronic pancreatitis (cp). the study hypothesizes that tea can be used as a non-pharmaceutical opioid-free approach to treat pain in chronic pancreatitis.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic pancreatitis (cp), based on a score greater or equal to 4 using a previously validated mayo scoring system that uses morphologic and functional criteria, or endosonographic features suggestive or consistent with cp based on rosemont criteria. * abdominal pain present at least once within the last month * willing and able to provide written informed consent exclusion criteria: * pregnancy or breastfeeding mother * imprisoned individuals * non-english speaking patients * scheduled for or with a history of pancreatic surgery (e.g. total pancreatectomy with islet auto transplantation (tpiat), puestow, frey, whipple, other) * currently undergoing or about to start endoscopic therapy with endoscopic retrograde cholangiopancreatography (ercp) or endoscopic ultrasound (eus) * recent history of acute pancreatitis as defined by the revised atlanta classification within a month prior to enrollment * radiologic and clinical findings consistent with symptomatic pseudocyst, wall-off necrosis, infected pancreatic necrosis, or biliary obstruction within the last 6 months * self-reported daily use of opioids for \> 12 months for weak opioids (codeine, tramadol and hydrocodone) or \> 6 months for strong opioids (other opioids) in the last two years. -self-reported ongoing illicit drug use or abuse- * suspected or diagnosed pancreatic cancer * receiving chemotherapy for cancer * known allergy to adhesive electrocardiogram (ecg) electrodes * patients with bilateral below the knee amputation * patients with lower extremity paralysis * patient is participating in another clinical trial * patients with an implantable electrical stimulation device.

Keywords: abdominal pain transcutaneous acustimulation
long-term safety study of bicifadine for the treatment of chronic low back pain

Conditions: Chronic Low Back Pain

Summary: the primary objective of the study is to evaluate the safety and efficacy of bicifadine 400 mg bid for up to one year in patients with moderate to severe chronic low back pain. the secondary objectives are to compare the long-term safety of bicifadine to standard of care therapy, to evaluate the safety of bicifadine following discontinuation of dosing, and to evaluate the safety and efficacy of lower doses of bicifadine in patients who do not tolerate bicifadine 400 mg bid.

there are two ways by which subjects could enter this study. subjects who completed 12 weeks of treatment in two other double blind clinical studies of bicifadine (studies 020 and 021, both in the united states) could roll over into this study. also, de novo subjects (that is, subjects who had not previously received bicifadine) could enroll in this study.

Eligibility criteria:
main inclusion criteria: * patients with low back pain assessed as class 1, class 2 or class 3 according to the quebec task force classification for spinal disorders and without detectable leg weakness on neurological examination. * patients must have required on average daily analgesics for the treatment of low back pain over the past 3 months prior to screening. main exclusion criteria: * patients may not have moderate or severe pain in a location other than the lower back (with the exception of radiation to the lower extremity) or weakness in the lower extremities. * patients must not have had epidural corticosteroid injections in the lower back within 1 month prior to baseline. * patients may not have an unstable medical condition.
analysis of in-hospital emergency team calls in a german tertiary care university hospital from 2013 to 2016

Conditions: Emergencies

Summary: a retrospective analysis of 1,664 emergency forms from met activities, ranging from january 2013 to december 2016. every met activation call via the emergency telephone number ("5555") and following emergency treatment was recorded by a standardized documentation form.

recent studies demonstrated that in-hospital emergencies are linked to a higher mortality in patients. in total, 1 out of 10 patients is suffering from an unexpected incident during the hospital stay. therefore, establishing and developing medical emergency teams (met) is getting more important in the future. aim of the present study was an analysis of medical documentation, operational tactics and procedures taken by met in a 4-year-period, ranging from 2013 to 2016. a retrospective analysis of 1,664 emergency forms from met activities, ranging from january 2013 to december 2016. every met activation call via the emergency telephone number ("5555") and following emergency treatment was recorded by a standardized documentation form.

Eligibility criteria:
inclusion criteria: * all patients treated with emergencies exclusion criteria: * none
a trial to determine radiation exposure to organs and assess the safety of cardiolite® in pediatric subjects

Conditions: Kawasaki Disease

Summary: the purpose of this phase i-ii multicenter clinical trial is to establish dosimetry and safety profiles for cardiolite® (technetium tc99m sestamibi) in pediatric subjects.


Eligibility criteria:
inclusion criteria: * have been scheduled to undergo a clinically indicated rest or stress cardiolite® mpi scan. * be able to comply with imaging requirements permitting completion of rest or stress cardiolite® whole-body scans and spect imaging procedures without the use of sedation. exclusion criteria: * have a terminal illness where expected survival is ≤6 months * have known clinically significant laboratory abnormalities (creatine, liver enzymes, platelet count).
deposition of terbinafine after iontophoretic application of ets terbinafine gel in subjects with distal subungual onychomycosis in the great toenail

Conditions: Onychomycosis

Summary: the purpose of this study is to determine how much terbinafine is delivered to the nail bed after treatment with a number of modifications to a previously studied method for iontophoretic delivery of terbinafine gel. iontophoretic delivery involves the use of a small electric charge to deliver drug across skin and nails.


Eligibility criteria:
inclusion criteria: * positive koh * 25-75% involvement of the visible nail. * nail plate must be \< 3 mm thick. * must have signed informed consent. * must agree to avoid any type of pedicure or application of any nail polish product or nail cosmetic to the toenails after the screening visit until day 28. * female subjects of childbearing potential must agree to take measures to avoid pregnancy until the day after day 28 * must agree to avoid the use of oral antifungals or topical terbinafine anywhere on the body until the day after day 28. topical antifungals other than terbinafine can be used on the body other than the feet after day 0. exclusion criteria: * presence of proximal subungual onychomycosis or white superficial onychomycosis * fungal involvement of a majority of the lunula * subjects with psoriasis, eczema, or other abnormalities that could result in a clinically abnormal nail * presence of dermatophytoma or onychomycotic spikes or exclusively lateral groove involvement * traumatized or dystrophic target great toenail. * known diabetics * subjects with peripheral vascular disease * subjects who are immunosuppressed (chronic corticosteroid therapy, solid organ or bone marrow transplantation, cytotoxic chemotherapy within the previous 12 months (or planned within the next 12 months), or hiv infection. * use of systemic corticosteroids within 30 days preceding day 0 * use of topical antifungals on the feet in the preceding 30 days of day 0 through day 28 * use of topical terbinafine in the 30 days prior to treatment through day 28 * use of systemic antifungals in the preceding 120 days of day 0 through day 28 * use of any investigational drug(s) within 30 days (120 days for systemic antifungals) preceding day 0 through day 28 * has previously participated in this study * is pregnant or is a nursing mother * women of of child bearing potential who are not using an adequate form of contraception (or abstinence) * subjects with pacemakers/automatic implantable cardioverter/defibrillators * subjects with an implantable electronic device. * subjects with a bleeding disorder or who are using warfarin or any other blood coagulation modulator including aspirin in the 14 days prior to treatment through day 28

Keywords: onychomycosis nail fungus tinea unguium
a non-significant risk clinical study to assess perfusion changes with application of a tus for patients with pad

Conditions: Peripheral Arterial Disease

Summary: the objective of the clinical trial is to gather evidence on the safety, performance and clinical efficacy vibrato sleeve tus in people with peripheral artery disease (pad).

subjects will be randomized to a test or control group and will receive an active or sham vibrato sleeve respectively. those randomized to the control arm will undergo therapy sessions with a sham vibrato sleeve device and two months of follow-up. upon completion of the 2-month follow-up visit, subjects will be informed of their randomization assignment. subjects in the sham arm will be allowed to crossover to a treatment regimen that uses an active vibrato sleeve device and will follow the same visit schedule as the active test group.

Eligibility criteria:
inclusion criteria: 1. age ≥22. 2. diagnosis of infrapopliteal pad. 3. rutherford class 4 or 5 as determined by the investigator. 4. toe brachial index (tbi) ≤ 0.6 or toe blood pressure ≤ 50 mmhg. exclusion criteria: 1. prior stenting in posterior tibial, anterior tibial or peroneal artery. 2. re-vascularization procedure within 25 days prior to enrollment in the study. (note: patients who had re-vascularization procedure earlier than 25 days prior to enrollment are eligible for enrollment if they meet other criteria). 3. ulcers, cellulitis, or skin breakdown in treatment areas (posterior calf). 4. history or diagnosis of severe chronic venous insufficiency or mixed arterio-venous disease. 5. acute limb ischemia within 30 days prior to treatment. 6. history or diagnosis of deep venous thrombosis below the knee in treatment leg. 7. uncontrolled diabetes defined as hba1c greater than 10%. 8. ongoing hyperbaric oxygen treatment (hbot) 9. any conditions that, in the opinion of the investigator, may render the patient unable to complete the study or lead to difficulties for patient compliance with study requirements, or could confound study data. 9. patient's enrollment in another investigational study that has not completed the required primary endpoint follow-up period (note: patients involved in a long-term surveillance phase of another study are eligible for enrollment in this study).

Keywords: therapeutic ultrasound (tus) peripheral artery disease (pad) critical limb ischemia (cli)
kuopio lutetium-177 study in patients with psma-positive metastatic prostate cancer

Conditions: Metastatic Prostate Adenocarcinoma; PSMA PET-Positive Castration-Resistant Prostate Cancer

Summary: kupsmalu-trial is an observational study for patients treated with 177lupsma-i\&t in kuopio university hospital, finland. study focuses on efficacy, safety and biomarker research.


Eligibility criteria:
inclusion criteria: 1. the patient must sign informed consent to participate in the study. 2. patients must be over 18 years of age. 3. patients must have histologically confirmed metastatic prostate adenocarcinoma. histological samples may show neuroendocrine features, but the primary component must be adenocarcinoma. 4. patients must have metastatic castration-resistant prostate cancer (mcrpc) that has been treated with at least docetaxel and abiraterone or enzalutamide, or the patients must have declined chemotherapy or be ineligible for docetaxel-based chemotherapy due to contraindications. 5. patients must have an adequate performance status: who 0-2. 6. castration must have been achieved either chemically (lhrh analog or antagonist) or surgically (orchiectomy). castration is defined as a low testosterone level (s-testosterone ≤ 1.7 mmol/l). 7. patients must have psma-positive tumor burden detected by 18f-psma-pet-ct imaging. 8. patients must have adequate renal and liver function (creatinine \< 2x upper limit of normal (uln), alt and alp \< 5x uln). 9. patients' blood counts must be within acceptable levels (hb ≥ 100 g/l, platelets ≥ 100 x 10⁹/l, leukocytes ≥ 3.0 x 10⁹/l, or neutrophils ≥ 1.0 x 10⁹/l). 10. the expected survival must be more than 6 months. 11. patients with ejaculatory capacity must commit to not donating sperm during the treatments and for 6 months after treatment completion. exclusion criteria: 1. patients whose physical condition and cooperation are insufficient to follow the given instructions. 2. patients who do not meet the criteria mentioned in the inclusion criteria. 3. patients must not have psma-negative tumor burden in the liver. the amount of psma-negative tumor burden must not exceed the amount of psma-positive tumor burden. 4. patients with symptomatic untreated spinal cord compression. 5. patients must not have acute hydronephrosis or urinary tract obstruction. 6. patients must not have a recurrent infection that impairs functional capacity.
cgm use in poorly controlled youth with type 1 diabetes

Conditions: Type 1 Diabetes; Hypoglycemia; High Blood Sugar

Summary: the purpose of this prospective study is to determine if trial use of a dexcom g6 cgm system for a 10 day wear period in high risk, poorly controlled pediatric type 1 diabetes patients increases uptake of personal cgm use, and improves short-term time in range glucose control.


Eligibility criteria:
inclusion criteria: * diagnosis of type 1 diabetes for \>3 months exclusion criteria: * cgm use in the last 6 months

Keywords: continuous glucose monitoring time in range hemoglobin a1c
effect of prone positionning in non intubated patients

Conditions: SARS-CoV 2 Pneumonia; Acute Respiratory Distress Syndrome; Prone Positioning

Summary: retrospective single center study on the effect of awake prone positioning in icu patients with severe hypoxemia related to sars-cov2

retrospective, observational study on the effects of awake prone positioning on oxygenation, invasive mechanical ventilation requirement and mortality in non intubation patients with severe hypoxemia related to sars-cov2 and regardeless of the oxygen supplementation method.

Eligibility criteria:
inclusion criteria: * all adult (\> 18 years) patients, non intubated, with acute respiratory failure due to covid-19 pulmonary infection exclusion criteria: * patients: hemodynamic instability and high doses of vasopressors * patients with contraindications of prone positioning: pregnancy, recent abdominal surgery * patients with pulmonay embolism * patients requiring invasive mechanical ventilation for extra respiratory reasons: neurological failure, urgent surgery
a canadian study to assess the safety of humate-p® ivr (infusion volume reduced)

Conditions: Von Willebrand Disease

Summary: as part of csl behring canada's continued commitment to ensuring the safety of the new low volume preparation of humate-p®, csl behring canada proposes to conduct a prospective, multi-center structured data collection of routine management of patients with von willebrand disease treated with humate p® ivr in canada. the surveillance will be non-interventional and non-experimental. during the observation period, the routine medical care of the patient will be documented. it is expected that there will be no difference in the safety and tolerability of humate-p® ivr compared to humate-p®


Eligibility criteria:
inclusion criteria: * male or female patients of any age; * patients who are suffering with von willebrand disease previously treated with humate-p®; * patients who are able to communicate well with the investigator and his/her representatives; * patients who are able and agreeing to comply with all study requirements; * patients who have provided written signed and dated informed consent prior to any study procedures being performed. exclusion criteria: * patients who have received any investigational drug ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.

Keywords: von willebrand disease vwd, humate-p® infusion volume reduced ivr